Compare NICE Ltd (NICE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs TG Therapeutics Inc — how do they compare? NICE Ltd trades at $98.28 (market cap $6.02B), while TG Therapeutics Inc trades at $49.65 (market cap $7.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| NICE | TGTX | |
|---|---|---|
Market Cap | $6.02B | $7.64B |
Sector | Technology | Health |
52-Week High | $153.44 | $59.06 |
52-Week Low | $83.15 | $26.94 |
Enterprise Value | $5.75B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $98.36, down 4.1% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $115. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 7.6% year-over-year, and maintains strong profitability with a net income margin of 13.86%. Recent news highlights partnerships with Currys and RingCentral to enhance AI-powered customer engagement.
The outlook for NICE is positive, supported by consistent earnings beats, solid valuation metrics, and expanding AI integrations. Key risks include competitive pressures in the CX software space and potential volatility from macroeconomic factors. With no sell ratings from analysts and institutional interest, the stock presents a growth opportunity amid manageable risks.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
